Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 189 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Quadrivalent influenza vaccine Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

NCT03308825
View directory record Official record
Conditions
Influenza, Flu
Interventions
Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Council Bluffs, Iowa • Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

NCT02207413
View directory record Official record
Conditions
Influenza
Interventions
Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 49 Years
Enrollment
1,886 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Wichita, Kansas • Rochester, New York • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 10, 2026, 6:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

NCT03884296
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Biological
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

NCT02831751
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain), Fluzone® High-Dose (60 µg/strain)
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Redding, California • Hollywood, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

NCT05330975
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 10, 2026, 6:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

NCT04460781
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent influenza vaccine RIV4, Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Up to 64 Years
Enrollment
96,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 2 Interventional

Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route

NCT03845231
View directory record Official record
Conditions
Influenza
Interventions
Flucelvax(R), Human Challenge virus
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

NCT05045144
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 10, 2026, 6:58 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
86
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

NCT06602024
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
40,805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
188
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

NCT05501561
View directory record Official record
Conditions
Influenza, Human
Interventions
Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1, Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years and older
Enrollment
1,056 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
47
States / cities
Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects

NCT04451954
View directory record Official record
Conditions
Influenza Immunisation, Healthy Volunteers
Interventions
Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 2 and adjuvant, Quadrivalent RIV with 2018-2019 NH H3 strain, Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

NCT04120194
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu, Fluzone Quadrivalent
Biological
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
2,654 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 10, 2026, 6:58 PM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

NCT02876159
View directory record Official record
Conditions
Influenza
Interventions
2016-2017 Influenza Vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
20 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 10, 2026, 6:58 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression

NCT03756246
View directory record Official record
Conditions
Depression, Healthy
Interventions
Influenza Vaccine
Biological
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

NCT05553301
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 10, 2026, 6:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 10, 2026, 6:58 PM EDT